Norman Gitlin, MD; Neil L. Julie, MD; Charles L. Spurr, MD; Kie N. Lim, MD; Herbert M. Juarbe, MD
Gitlin N., Julie N., Spurr C., Lim K., Juarbe H.; Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone. Ann Intern Med. 1998;129:36-38. doi: 10.7326/0003-4819-129-1-199807010-00008
Download citation file:
Published: Ann Intern Med. 1998;129(1):36-38.
Several oral antihyperglycemic agents are available for management of type 2 diabetes. These agents generally fall into the chemical or function groups sulfonylureas, biguanides, or α-glucosidase inhibitors. Recently, the U.S. Food and Drug Administration approved troglitazone (Rezulin, Parke-Davis, Morris Plains, New Jersey), a thiazolidinedione agent that is unrelated to the aforementioned categories, as a novel oral antihyperglycemic agent. It decreases hepatic glucose output and increases insulin-dependent glucose metabolism in skeletal muscle [1, 2]. It is not an insulin secretagogue. We report two patients who had severe hepatotoxicity associated with troglitazone administration.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Emergency Medicine, Gastroenterology/Hepatology, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only